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Dendritic cells (DC) are efficient and potent antigen-presenting cells in our immune 
system. The ability of DC to present antigens and stimulate T cells has prompted 
their application as therapeutic cancer vaccines. The objective of this study was to 
generate DC from two resources: monocytes and AML blasts. The generated DC 
were evaluated for their morphology by phase contrast microscopy and May 
Grunwald Giemsa staining. Viability of cells was determined by trypan blue dye 
exclusion. Percentage of yields and immunophenotypes were carried out with flow 
cytometry. The functional capability of DC was also tested in Mixed Leukocyte 
Reactions and anti-leukaemia cytotoxicity assay. As a result, the generated DC 
shown typical morphology of those reported and expressed DC surface markers 
including CDl a, CD83, CD86, CD80 and HLA-DR. Down regulation of CD14 was 
also observed for cultured monocytes. In MLR assay, both generated DC elicited 
strong allo-stimulatory response up to more than 100 fold compared to preculture 
cells. Mild anti-leukaemia cytotoxicity effect (1 5%) was also observed fiom primed 
effector cells with AML antigen pulsed DC generated fiom monocytes. These data 
indicate that DC were successfully generated fiom the two resources and they were 
capable of eliciting immune response. 
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Sel dendritik (DC) merupakan sel yang efisien dan penting dalam pemaparan 
antigen di dalam sistem imun kita. Kebolehan DC untuk memaparkan antigen dan 
merangsang sel T telah mencungkilkan penggunaan sel ini sebagai vaksin kanser 
dalam terapiutik. Objektif kajian ini adalah untuk menghasilkan DC daripada dua 
jenis surnber iaitu monosit dan blas leukemia mieloid akut (AML). DC yang 
dihasilkan dikaji dari segi morfologi dengan menggunakan mikroskopi berfasa 
kontras dan pewarnaan May Grumwald Giemsa. Kehidupan sel ditentukan dengan 
cara pengecualian pewarnaan tripan biru. Peratusan penghasilan dan imunofenotip 
DC ditentukan dengan cam aliran sitometri. Kebolehan fungsi DC ditentukan 
dengan asai Reaksi Campuran Leukosit dan sitotoksik anti-leukaemia. Sebagai 
keputusan, DC yang dihasilkan menunjukkan morfologi yang tipikal sepertimana 
yang dilaporkan dan mengekspres pelbagai tanda permukaan DC termasuk CD 1 a, 
CD83, CD86, CD80 dan HLA-DR. P e n m a n  ekspresi CD14 daripada monosit 
yang telah dikultur juga diperhatikan. Dalam asai Reaksi Campuran Leukosit, 
kedua-dua DC yang dihasilkan berjaya menjana respons alo-stimulasi yang kuat 
iaitu lebih daripada 100 kali berbanding dengan sel yang belum dikultur. Kesan 
sitotoksik anti-leukaemia yang sederhana (1 5%) diperhatikan daripada sel efektor 
yang telah dikultur bersamaan dengan DC yang dihasilkan daripada monosit dan 
telah dipaparkan kepada antigen AML. Semua data di atas menunjukkan bahawa 
DC telah berjaya dihasilkan daripada dua jenis sumber tersebut dan berfungsi 
dalam menjana respons imun. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Importance of DC as Professional Antigen Presenting Cells (APC) 
The immune system in mice and human contains a distinct group of APC, called 
dendritic cells (DC) that are specialized to capture antigens and initiate T cell 
immunity. DC are named because of their distinctive morphology with numerous 
cell membrane processes, including spiny dendrites, bulbous pseudopods and 
lamellipodiae or veils (reviewed by Hart, 1997), as shown in Figure 1. The first DC 
were reported in the skin by Langerhans in 1868. This was followed by Steiman 
and Cohn who identified mouse spleen DC in 1973 and initiated a series of 
experiments that established lymphoid-tissue derived DC as potent stimulators of 
primary immune responses. 
The term "Professional Antigen Presenting Cells" is used to denote cells that have 
both antigen-presenting and accessory or costimulatory functions (Steinman, 1999). 
Despite other APC such as B cells and macrophages, DC are more "professional" 
because of their extraordinary capacity for initiating primary T-lymphocyte 
responses. This is because in addition to processing antigens to peptides that are 
presented on MHC, DC also express a plethora of second signals that mediate T- 
cell binding and costimulation. Most of these second signals are membrane 
glycoproteins such as intracellular adhesion molecules (ICAMs; CD50, CD54, 
CD102), and lymphocyte function associated antigens (LFAa) (CD2, CDl la, 
CD58), and B7(CD80 and CD86). 
1.2 Dendritic Cell Lineages and Nomenclature 
Generally, there are two types of DC; one is myeloid-derived DC from myeloid 
stem cells and lymphoid-derived DC from lymphoid stem cells (Hart, 1997). 
Myeloid-derived DC are distributed in a way that maximizes antigen capture and 
subsequently the binding and activation of specific T cells (Figure 2). They could 
be found in lymphoid organs, such as lymph node, tonsil, spleen, thymus and 
mucosa-associated lymphoid tissue. Myeloid-derived DC are represented in vivo by 
Langerhans cells (LC) and interstitial DC. The DC found in epidermis were named 
Langerhans cells. Most organs except the brain have MHC-11- rich DC within the 
interstitial spaces that are drained by afferent lymphatics. These DC are known as 
dermal (interstitial) dendritic cells and those in afferent lymph are recognized as 
veil cells. 
Lymphoid lineage-derived DC have different roles compared to myeloid-lineage 
derived DC. They play an important role in T cells selection and tolerance in the 
thymus. Lymphoid DC are abundant in thymus and T cell area of lymph node 
where they are known as Interdigitating Cells (IDC). B cell areas of lymph node are 
rich in another type of cells called the Follicular DC (FDC) that are not originated 
from the bone marrow (Bachereau and Steinman, 1998). FDC are likely to be 
stromal or fibroblast cells because they do not express the CD45 molecule that is 
found on all leukocytes and because they share properties with fibroblasts in 
culture. FDC retain native antigens as immune complexes for presentation to B 
cells. Therefore, apart from a coincidence in nomenclature, FDC bear little relation 
to DC, which are marrow-derived leukocytes that present processed antigens to T 
cells. 
Distribution of 
DC 
Figure 2: Distribution of DC in human body. 
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1.3 DC Vaccines for Cancer Immunotherapy 
Human turnours express a number of protein antigens that can be recognized by T 
cells, thus providing potential targets for cancer immunotherapy (Schreiber, 1993). 
The ability of DC to present antigens and stimulate T cells has prompted their 
recent application as therapeutic cancer vaccines (Timmerman and Levy, 1999). 
Isolated DC loaded with turnour antigen ex vivo and administered as a cellular 
vaccine have been found to induce protective and therapeutic anti-tumour immunity 
in experimental animals (Mayordomo et al., 1995). In pilot clinical trials of DC 
vaccination for patients with multiple myeloma, melanoma and prostate cancer, 
induction of anti-tumour immune responses and tumour regressions have been 
observed (reviewed by Timmerman and Levy, 1999). Additional trials of DC 
vaccination for a variety of human cancers had been reported, and new methods for 
targeting turnour antigens to DC also being explored (reviewed by Timmerman and 
Levy, 1999). Exploitation of the antigen-presenting properties of DC thus offers 
promise for the development of effective cancer immunotherapies. 
